Earendil: A Blueprint for a Multipolar Life Sciences Era
The $787M financing points to a new global architecture in biotech
False
The $787M financing points to a new global architecture in biotech
False
False
September 10, 2026
8 min read
Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology
September 8, 2026
4 min read
Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy
September 4, 2026
2 min read
Peng Lu argues that small molecules remain indispensable as AI transforms drug development
September 3, 2026
7 min read
Members of The Medicine Maker’s 2026 Power List predict how AI, new modalities, integrated data, and shifting global markets will reshape the industry
False
Affiliations:
Specialties:
Areas of Expertise:
4 Topic Commentaries
Earendil: A Blueprint for a Multipolar Life Sciences Era
Julio Frenk, MD, MPH, PhD
Global health policy and health systems
•Harvard University
Nalini Anand, JD, MPH
Global health policy and research administration
•Georgetown University
Andrew Forsyth, PhD
Global health research policy and analytics
•Fogarty International Center, National Institutes of Health
Cassidy R. Sugimoto, PhD
Science of science and science policy
•Georgia Institute of Technology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.